Introduction
Type 2 diabetes mellitus (T2DM) and osteoporosis are common chronic diseases, and the relationship between the two is becoming a hot research topic.1,2 Previous studies have shown that although bone mineral density (BMD) is normal or elevated,3 T2DM patients increase the risk of fractures compared with non-diabetic patients.46 T2DM can influence bone metabolism by affecting osteoblasts and osteoclasts, and the imbalance between the two may lead to osteoporosis.7 It has been confirmed that there are insulin receptors on the surface of both cells,8 and insulin signaling can regulate the bone formation of osteoblasts and bone resorption of osteoclasts.9 In vitro, it has been shown that the physiological concentration of insulin can increase the proliferation rate of osteoblasts, collagen synthesis, alkaline phosphatase production, and glucose uptake and inhibit osteoclast activity.10 Thus, insulin is an anabolic agent for bone formation, and elevated insulin levels may increase bone density.11,12 It has been widely accepted that insulin resistance is the main problem of T2DM metabolic disorders. It is caused by the defect in the insulin signaling pathway that reduces the cellular insulin response; pancreatic cells overcome the reduced sensitivity by enhancing insulin secretion, thereby developing hyperinsulinemia.9,13 Hyperinsulinemia can also negatively affect sex hormone-binding globulin to increase free sex hormone levels, preventing bone loss.11,14
However, more and more studies have shown a negative association between insulin resistance and bone mineral density,11,15,16 indicating that insulin resistance in T2DM patients may weaken the physiological effects of insulin on bones.1 Therefore, the relationship between insulin resistance and osteoporosis is still controversial. To address this question, in this study, we used a C peptide to evaluate insulin resistance based on the modified insulin resistance homeostasis model (HOMA-IR) and explored the relationship between HOMA-IR (CP) and the risk of osteoporosis in different gender groups of T2DM patients.
This was a cross-sectional study. We selected 575 T2DM patients from the outpatient department of Endocrinology and Metabolism at our hospital from February 2016 to August 2018. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Ethics Committee of the Third Affiliated Hospital of Soochow University for retrospective analysis (ethics number: 2014-KD-79). The sample size calculation used the method of computer simulation inspection efficiency (see Supplementary Material-Computer simulation inspection efficiency). Since the patients were anonymous, informed consent was not required. Inclusion criteria: T2DM was defined as: fasting blood glucose level 7.0 mmol/l, 2 hours postprandial or random blood glucose level 11.1 mmol/l, glycosylated hemoglobin (HbA1c) 6.5%. Record the patients use of T2DM treatment drugs. The following patient populations were excluded: (1) patients using hormone replacement therapy, bisphosphonates, glucocorticoids, proton pump inhibitors, etc. (14 cases); (2) patients with missing bone density results (311 cases); (3) patients under 18 years old (1 case); (4) patients with missing HOMA-IR (CP) (15 cases). The research flow chart is shown in Figure 1. Among the 250 patients with available BMD data and the 311 patients with missing BMD data, almost all clinical factors were similar (all P > 0.05) (see Supplementary Table S1).
Figure 1 Flowchart of the study.
The general data of the patient was recorded, including menopause information. The height, weight, waist circumference, and hip circumference of patients were measured, and the body mass index (BMI) and waist-to-hip ratio were calculated. The fasting venous blood was collected, and the fasting blood glucose, uric acid, and blood lipid levels were measured using an automatic biochemical analyzer (Beckman Coulter AU5800, Brea, CA, USA). Fasting C peptide was determined by electrochemiluminescence immunoassay (Roche Cobas8000, Indianapolis, IN, USA). HbA1c was measured by high-performance liquid chromatography (D-10 system, Bio-Rad, USA).
Instead of insulin, fasting C-peptide was used to evaluate insulin resistance and islet function according to a modified formula. The modified HOMA-IR [HOMA-IR (CP)] formula = 1.5 + fasting blood glucose (mmol/L) fasting C-peptide (pmol/L)/2800. The modified HOMA-islet [HOMA-islet (CP-DM)] formula = 0.27 fasting C-peptide (pmol/L)/[fasting blood glucose (mmol/L) 3.5].17
The dual-energy X-ray absorptiometry (DXA, Hologic, Discovery-WI, USA) was used to determine the bone density of the lumbar spine (L1-L4) (unit: g/cm2). Trained and certified technicians performed all DXA scans. The diagnosis of osteopenia and osteoporosis was based on the T score of the World Health Organization (the T value was the standard deviation between the patient BMD and the BMD of the young adult reference population). 2.5 < T value < 1.0 was defined as osteopenia, T value 2.5 was defined as osteoporosis.18
Data were expressed as mean standard deviation (SD) (Gaussian distribution) or median (Q1-Q3) (Skewed distribution) for continuous variables and as numbers or percentages for categorical variables. To examine the association between HOMA-IR (CP) and osteoporosis risk, we constructed three distinct models using univariate and multivariable binary logistic regression models, including non-adjusted model, minimally-adjusted model (Adjust I), and fully-adjusted model (Adjust II). Covariates were included as potential confounders in the final models if they changed the estimation of HOMA-IR (CP) on osteoporosis by more than 10% or significantly associated with osteoporosis (P < 0.10). The subgroup analyses were performed using a stratified binary logistic regression model. The effect sizes with 95% confidence intervals were recorded. To investigate the nonlinear relationship between HOMA-IR (CP) and osteoporosis risk, we used a generalized additive model and smooth curve fitting (penalized spline method) to address nonlinearity. Moreover, the two-piecewise binary logistic regression model was used to explain the nonlinearity further.
Modeling was performed with the statistical software R (http://www.R-project.org, The R Foundation) and EmpowerStats (http://www. empowerstats.com, X&Y Solutions, Inc, Boston, MA). P < 0.05 (two-sided) was considered statistically significant.
A total of 234 T2DM patients were included in the study, with 139 males and 95 females, aged 57.5 10.8 years old (range: 2383 years old). Among them, 112 cases were first diagnosed (no hypoglycemic drugs were used), 122 cases were controlled by drugs (including 55 metformin, 37 acarbose, 24 sulfonylureas, 12 insulin, and 5 thiazolidinediones, new hypoglycemic drugs [including glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors] 2 cases, some patients have combined medication). The results of BMD measurement showed that there were 82 cases (35.0%) with normal bone mass, 118 cases (50.4%) with osteopenia, and 34 cases (14.5%) with osteoporosis. The general information and blood indicators of different gender groups are shown in Table 1.
Table 1 Comparison of General Information and Blood Indicators of Different Gender Groups
Compared with male T2DM patients, female patients were older (P = 0.047) and had longer disease course (P = 0.013), and have a higher proportion of drug control (P = 0.012); but their BMI, waist-to-hip ratio, fasting blood glucose, fasting C-peptide, HOMA-IR (CP), HOMA-islet (CP-DM), and HbA1c were not significantly different (all P > 0.05). The osteoporosis percentage in female patients was slightly higher than that in male patients (15.8% vs 13.7%), but the difference was insignificant (P = 0.651).
The univariate logistic regression analysis was performed by taking osteoporosis as the dependent variable (Y = 1) and using the clinical data and blood indicators from different gender groups as independent variables (see Table 2). The results showed that age, uric acid, and HOMA-IR (CP) were all possible related factors for osteoporosis in female patients (P < 0.10), while in male patients, the association between the above indicators and osteoporosis was not significant (P > 0.10).
Table 2 Univariate Analysis of Clinical Data, Blood Indicators, and Osteoporosis of Different Gender Groups
Multivariable logistic regression analysis was used to evaluate the association between HOMA-IR (CP) and osteoporosis by adjusting the covariates. The model with non-adjusted covariates equaled to univariate logistic regression analysis. The minimally-adjusted covariates (Adjust I) included age and uric acid, and the fully-adjusted covariates (Adjust II) included age, BMI, waist-to-hip ratio, disease course, HOMA-islet (CP-DM), uric acid, triacylglycerol, and high-density lipoprotein (see Table 3). For female patients, the increase in HOMA-IR (CP) elevated the risk of osteoporosis in all regression models with non-adjusted, minimally-adjusted, and fully-adjusted covariates, and the association was significant in the fully-adjusted model, with OR = 2.63 (95% CI: 1.155.99, P = 0.022). For male patients, the association between HOMA-IR (CP) and osteoporosis was not significant in all three models (all P > 0.05). The interaction effect between different genders was significant (P for interaction all < 0.05), indicating that the relationship between HOMA-IR (CP) and osteoporosis was affected by gender.
Table 3 Multivariable Logistic Regression Analysis of the Effect of HOMA-IR (CP) on Osteoporosis
GAM was used to test the relationship between HOMA-IR (CP) and osteoporosis risk in female patients. The results showed a nonlinear relationship between the two after correcting for age, BMI, waist-to-hip ratio, disease course, HOMA-islet (CP-DM), uric acid, triacylglycerol, and high-density lipoprotein (degree of freedom was 1.862, P = 0.024). Figure 2 showed the changes of osteoporosis risk with HOMA-IR (CP) in female patients: at first, the changes were very little; after a certain HOMA-IR (CP) value, the osteoporosis risk significantly increased, showing a piecewise linear relationship. By observing the fitted curve, we set the inflection point as 4.00.
Figure 2 The relationship between HOMA-IR (CP) and osteoporosis risk. Adjust for: age, BMI, waist-to-hip ratio, disease course, HOMA-islet (CP-DM), uric acid, triacylglycerol, and high-density lipoprotein.
Abbreviations: HOMA-IR (CP), homeostasis model assessment for insulin resistance based on C-peptide; BMI, body mass index; HOMA-islet (CP-DM), homeostasis model assessment islet beta-cell function based on C-peptide.
The two-piecewise logistic regression model method was used further to evaluate the threshold effect of the fitted curve. The log-likelihood ratio test of HOMA-IR (CP) at the inflection point 4.00 was statistically significant (P = 0.005), suggesting that the two-piecewise regression model was appropriate for describing the relationship between HOMA-IR (CP) and osteoporosis (see Table 4). When HOMA-IR (CP) < 4.00, the risk of osteoporosis in female patients did not change much with HOMA-IR (CP), (P = 0.474); when HOMA-IR (CP) > 4.00, the increase in HOMA-IR (CP) significantly elevated the risk of osteoporosis in female patients, with OR = 26.88 (95% CI: 2.75262.69, P = 0.005).
Table 4 Nonlinear Relationship Between HOMA-IR (CP) and Osteoporosis
The relationship between insulin resistance and the risk of osteoporosis in T2DM patients is still controversial. Our study found that this relationship was significantly affected by gender. In female patients, the higher the degree of insulin resistance, the greater the risk of osteoporosis. However, the relationship was not a simple linear relationship, and there was a threshold effect. When HOMA-IR (CP) > 4.00, the risk of osteoporosis increased significantly.
The incidence of osteoporosis is gradually increasing in recent years, which affects the patients life quality and causes serious social health problems.19,20 Many factors are related to osteoporosis, including age, gender, endocrine, and metabolic diseases.21 The age-related reduction of sex hormones is one reason for osteoporosis, as sex hormones play an important role in maintaining bone health.22 Compared with older males, hormone deficiency is more pronounced in older females.23 Diabetes is also an important cause of osteoporosis. Many studies2,24 have shown that people with T2DM have a higher risk of bone fractures than non-diabetic patients. Our study showed that the proportion of osteoporosis in female T2DM patients was higher than that of male patients, consistent with the previous studies.
T2DM is the most common endocrine system disease in the clinic, with insulin resistance as the basic pathological feature, accompanied by internal environmental disorders and abnormal synthesis and secretion of various cytokines. These effects influence bone metabolism and then cause bone loss and destruction of bone ultrastructure.25 In recent years, studies have shown that insulin directly affects bone cells,14 but the relationship between insulin resistance and osteoporosis is still unclear. Bilic-Curcic et al26 proposed that abdominal obesity and hyperinsulinemia played a protective role in postmenopausal women with T2DM, leading to an increase in the total femoral bone density. A cohort study of the elderly27 showed that insulin resistance was associated with increased bone density. The synergistic effect of excess insulin and other anabolic hormones, such as pancreatic amylin, insulin-like growth factors, and parathyroid hormone, can increase bone density.28 However, our results were different, which might be due to the heterogeneity of the study population, such as age, gender, race, and menopause. In addition, we used a modified HOMA-IR model to evaluate insulin resistance, in which C-peptide replaced insulin. C-peptide is more stable and is considered an effective substitute for insulin.29 Moreover, the bone density we measured was based on the lumbar spine, which might also cause inconsistent results. It has been reported30 that significant insulin resistance in T2DM patients is associated with low bone density. T2DM patients are often accompanied by mild inflammation, and chronic inflammation can lead to the development of osteoporosis through oxidative stress.31 Weber et al (31) speculated that the relationship between insulin resistance and osteoporosis might not be linear, and there was a threshold effect. Our results confirmed this perspective. When HOMA-IR (CP) > 4.00, the higher the insulin resistance of female T2DM patients, the greater the risk of osteoporosis. In our study, the proportion of female patients who had menopause accounted for 85.3%. The sharp decline in estrogen after menopause led to the loss of bone mass. This gender difference may affect the relationship between insulin resistance and osteoporosis.32 In addition, with the increase of insulin resistance, other related factors, such as pro-inflammatory cytokines, have also increased, which exerts an adverse effect on bone health, exceeding the anabolic effect of insulin on bone and leading to decreased bone density.11,33
Our study has some limitations. Firstly, this is a single-center retrospective study. There were only 34 patients with osteoporosis, and there was a high proportion of missing BMD results. The sample size needs to be expanded to obtain a more accurate HOMA-IR (CP) threshold. Secondly, there might be unknown confounding factors that affected our results. For example, serum 25-hydroxyvitaminD27,34 and diabetes medications35 are important factors that affect bone health. Finally, this study only found a significant association between HOMA-IR (CP) and osteoporosis in female patients, and more male patients should be collected for further research. The relationship between insulin resistance and osteoporosis is complex and has not been fully understood. Further research is needed to clarify the relationship between the two.
In summary, the relationship between insulin resistance and osteoporosis risk in T2DM patients is significantly affected by gender. The higher the degree of insulin resistance in female T2DM patients, the greater the risk of osteoporosis. Moreover, this relationship is not simply linear, and there is a threshold effect. This study will help clinicians assess the risk of osteoporosis in T2DM female patients and make appropriate early interventions.
All data generated or analyzed during this study are available from the corresponding author upon reasonable request.
The study was approved by the Institutional Ethics Committee of the Third Affiliated Hospital of Soochow University for retrospective analysis (ethics number: 2014-KD-79).
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
There is no funding to report.
The authors report no conflicts of interest in this work.
1. Ahmad OS, Leong A, Miller JA, et al. A mendelian randomization study of the effect of type-2 diabetes and glycemic traits on bone mineral density. J Bone Miner Res. 2017;32(5):10721081. doi:10.1002/jbmr.3063
2. Xu Y, Wu Q. Trends in osteoporosis and mean bone density among type 2 diabetes patients in the US from 2005 to 2014. Sci Rep. 2021;11(1):3693. doi:10.1038/s41598-021-83263-4
3. Zhu L, Xu Z, Li G, et al. Marrow adiposity as an indicator for insulin resistance in postmenopausal women with newly diagnosed type 2 diabetes - an investigation by chemical shift-encoded water-fat MRI. Eur J Radiol. 2019;113:158164. doi:10.1016/j.ejrad.2019.02.020
4. Looker AC, Eberhardt MS, Saydah SH. Diabetes and fracture risk in older U.S. adults. Bone. 2016;82:915. doi:10.1016/j.bone.2014.12.008
5. Napoli N, Strotmeyer ES, Ensrud KE, et al. Fracture risk in diabetic elderly men: the MrOS study. Diabetologia. 2014;57(10):20572065. doi:10.1007/s00125-014-3289-6
6. Jia P, Bao L, Chen H, et al. Risk of low-energy fracture in type 2 diabetes patients: a meta-analysis of observational studies. Osteoporos Int. 2017;28(11):31133121. doi:10.1007/s00198-017-4183-0
7. Sassi F, Buondonno I, Luppi C, et al. Type 2 diabetes affects bone cells precursors and bone turnover. BMC Endocr Disord. 2018;18(1):55. doi:10.1186/s12902-018-0283-x
8. Fulzele K, Riddle RC, DiGirolamo DJ, et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142(2):309319. doi:10.1016/j.cell.2010.06.002
9. Conte C, Epstein S, Napoli N. Insulin resistance and bone: a biological partnership. Acta Diabetol. 2018;55(4):305314. doi:10.1007/s00592-018-1101-7
10. Thrailkill KM, Lumpkin CK, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289(5):E735745. doi:10.1152/ajpendo.00159.2005
11. Shin D, Kim S, Kim KH, Lee K, Park SM. Association between insulin resistance and bone mass in men. J Clin Endocrinol Metab. 2014;99(3):988995. doi:10.1210/jc.2013-3338
12. Nyman JS, Kalaitzoglou E, Clay bunn R, Uppuganti S, Thrailkill KM, Fowlkes JL. Preserving and restoring bone with continuous insulin infusion therapy in a mouse model of type 1 diabetes. Bone Rep. 2017;7:18. doi:10.1016/j.bonr.2017.07.001
13. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2008;31(Suppl 2):S262268. doi:10.2337/dc08-s264
14. Shanbhogue VV, Finkelstein JS, Bouxsein ML, Yu EW. Association between insulin resistance and bone structure in nondiabetic postmenopausal women. J Clin Endocrinol Metab. 2016;101(8):31143122. doi:10.1210/jc.2016-1726
15. Ahn SH, Kim H, Kim BJ, Lee SH, Koh JM. Insulin resistance and composite indices of femoral neck strength in Asians: the fourth Korea National Health and Nutrition Examination Survey (KNHANES IV). Clin Endocrinol (Oxf). 2016;84(2):185193. doi:10.1111/cen.12958
16. Shah VN, Sippl R, Joshee P, et al. Trabecular bone quality is lower in adults with type 1 diabetes and is negatively associated with insulin resistance. Osteoporos Int. 2018;29(3):733739. doi:10.1007/s00198-017-4353-0
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412419. doi:10.1007/BF00280883
18. Golob AL, Laya MB. Osteoporosis: screening, prevention, and management. Med Clin North Am. 2015;99(3):587606. doi:10.1016/j.mcna.2015.01.010
19. Ma C, Tonks KT, Center JR, Samocha-Bonet D, Greenfield JR. Complex interplay among adiposity, insulin resistance and bone health. Clin Obes. 2018;8(2):131139. doi:10.1111/cob.12240
20. Cosman F, de Beur SJ, LeBoff MS, et al. Clinicians Guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):23592381. doi:10.1007/s00198-014-2794-2
21. Rubin MR, Schwartz AV, Kanis JA, Leslie WD. Osteoporosis risk in Type 2 diabetes patients. Expert Rev Endocrinol Metab. 2013;8(5):423425. doi:10.1586/17446651.2013.835567
22. Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279302. doi:10.1210/edrv.23.3.0465
23. Sawicki P, Talalaj M, Zycinska K, Zgliczynski WS, Wierzba W. A cross-sectional comparison of selected anthropometric, laboratory and densitometric parameters in postmenopausal osteoporotic women with and without vertebral compression fractures. Endokrynol Pol. 2021;72(3):191197. doi:10.5603/EP.a2021.0011
24. Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016;27(1):219228. doi:10.1007/s00198-015-3279-7
25. Heilmeier U, Patsch JM. Diabetes and Bone. Semin Musculoskelet Radiol. 2016;20(3):300304. doi:10.1055/s-0036-1592366
26. Bilic-Curcic I, Makarovic S, Mihaljevic I, Franceschi M, Jukic T. Bone mineral density in relation to metabolic syndrome components in postmenopausal women with diabetes mellitus type 2. Acta Clin Croat. 2017;56(1):5863. doi:10.20471/acc.2017.56.01.09
27. Napoli N, Conte C, Pedone C, et al. Effect of Insulin resistance on BMD and fracture risk in older adults. J Clin Endocrinol Metab. 2019;104(8):33033310. doi:10.1210/jc.2018-02539
28. Fornari R, Marocco C, Francomano D, et al. Insulin growth factor-1 correlates with higher bone mineral density and lower inflammation status in obese adult subjects. Eat Weight Disord. 2018;23(3):375381. doi:10.1007/s40519-017-0362-4
29. Fasipe OJ, Ayoade OG, Enikuomehin AC. Severity grade assessment classifications for both insulin resistance syndrome and status of pancreatic beta cell function in clinical practice using homeostasis model assessment method indices. Can J Diabetes. 2020;44(7):663669. doi:10.1016/j.jcjd.2020.02.003
30. Arikan S, Tuzcu A, Bahceci M, Ozmen S, Gokalp D. Insulin resistance in type 2 diabetes mellitus may be related to bone mineral density. J Clin Densitom. 2012;15(2):186190. doi:10.1016/j.jocd.2011.11.005
31. Tonks KT, White CP, Center JR, Samocha-Bonet D, Greenfield JR. Bone Turnover is suppressed in insulin resistance, independent of adiposity. J Clin Endocrinol Metab. 2017;102(4):11121121. doi:10.1210/jc.2016-3282
32. Mesinovic J, McMillan LB, Shore-Lorenti C, et al. Sex-specific associations between insulin resistance and bone parameters in overweight and obese older adults. Clin Endocrinol (Oxf). 2019;90(5):680689. doi:10.1111/cen.13947
33. Cao JJ. Effects of obesity on bone metabolism. J Orthop Surg Res. 2011;6:30. doi:10.1186/1749-799X-6-30
34. Gagnon C, Lu ZX, Magliano DJ, et al. Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: ausDiab). J Clin Endocrinol Metab. 2012;97(6):19531961. doi:10.1210/jc.2011-3187
35. Lee HS, Hwang JS. Impact of type 2 diabetes mellitus and antidiabetic medications on bone metabolism. Curr Diab Rep. 2020;20(12):78. doi:10.1007/s11892-020-01361-5
Read the original:
Association Analysis of Insulin Resistance and Osteoporosis Risk in Ch | TCRM - Dove Medical Press
- Pharmac seeking bids from suppliers to fund another type of hormone replacement therapy - New Zealand Doctor Online - April 5th, 2024
- What is Hormone Replacement Therapy and how safe is it? - PinkNews - March 19th, 2024
- Menopausal Hormone Therapy | Johns Hopkins Medicine - January 6th, 2024
- Find a Provider - Biote - January 6th, 2024
- Biote Certified Providers By State - Biote - January 6th, 2024
- Is Hormone Replacement Therapy Right for You? What to Know - Motherly Inc. - January 6th, 2024
- Hormone Replacement Therapy - StatPearls - NCBI Bookshelf - February 6th, 2023
- Natural hormone replacement therapy: How it works - Medical News Today - February 6th, 2023
- Hormone replacement therapy (HRT) - Types - NHS - December 27th, 2022
- Helping Reduce Your Risk of Breast Cancer ThedaCare - ThedaCare - October 13th, 2022
- 'How Hormone Replacement Therapy Impacted My Strength Training' - Women's Health - October 13th, 2022
- This Simple Blood Test Gives Incredible Insights Into Building Muscle Mass - Yardbarker - October 13th, 2022
- Take strides to raise awareness of breast cancer - Theredstonerocket - October 13th, 2022
- Breast cancer and hormone therapy | GNP online - brytfmonline.com - October 13th, 2022
- Early detection matters | Marshall Medical employee recounts her breast cancer journey - Sand Mountain Reporter - October 13th, 2022
- Hormone replacement therapy (HRT) - Benefits and risks - NHS - October 4th, 2022
- Thyroid Hormone Replacement Therapy | Johns Hopkins Medicine - October 4th, 2022
- Prescribing HRT in women with migraine The Medical Republic - The Medical Republic - October 4th, 2022
- Caring for the gynecologic needs of the adolescent patient - Contemporary Obgyn - October 4th, 2022
- Im a GP heres the best way to treat acne and when to see a doctor... - The US Sun - October 4th, 2022
- State-by-state prevalence of the 5 most common types of cancer - KFOR Oklahoma City - October 4th, 2022
- How Menopause Affects Cholesterol And What to Do About It - TIME - September 25th, 2022
- Stroke symptoms in men & women - Times of India - September 25th, 2022
- Turn back the clock with collaborative care solutions Peace Arch News - Peace Arch News - September 25th, 2022
- Health benefits of flaxseed - Punch Newspapers - September 25th, 2022
- Progesterone Market Size to Grow by USD 1.23 Billion, Rise in Research and Development of Progesterone Drugs -Technavio - Yahoo Finance - September 25th, 2022
- Hormone Replacement Therapy for Menopause - Healthline - September 16th, 2022
- Hormone Replacement Therapy Market to Hit Value of $29.65 Billion by 2028 | Looming Shortage HRT Products to be a Key Challenge - GlobeNewswire - September 16th, 2022
- This Is How Long It Takes For Hormone Replacement Therapy To Start Working - Health Digest - September 16th, 2022
- Progesterone to be fully funded for all who need it in 'a welcome change' - Stuff - September 16th, 2022
- Contributor: In the Misdiagnosis of Menopause, What Needs to Change? - AJMC.com Managed Markets Network - September 16th, 2022
- Premenstrual syndrome: Real-life impact and coping strategies - Medical News Today - September 16th, 2022
- Why you should be paying attention to Ohio Supreme Court races - News 5 Cleveland WEWS - September 16th, 2022
- When You Take Vitamin C Every Day, Here's What Happens Eat This Not That - Eat This, Not That - September 16th, 2022
- Using HRT (Hormone Replacement Therapy) - breast cancer - September 8th, 2022
- Bioidentical Hormone Replacement Therapy for Men - September 8th, 2022
- Hormone Replacement Therapy for Over 60s | Gransnet - September 8th, 2022
- Rethinking "The Change": Discover 40+ Ways to Embrace Menopause - PR Newswire - September 8th, 2022
- Seven days in medicine: 31 Aug to 6 Sep 2022 - The BMJ - September 8th, 2022
- If Covid Distorted Your Sense Of Time, Don't Panic: You're In The Majority - Kaiser Health News - September 8th, 2022
- Hot Flashes Can Impact Up to 80% of Women So Why Arent We Talking About It? - SheKnows - August 30th, 2022
- Woman shares the frustrations of going through menopause at age 49 - Insider - August 30th, 2022
- F*cking Ridiculous! Scotland Is Championing Menopause But Got One Big Thing Wrong - Suggest - August 30th, 2022
- Hunter Schafer Criticized For Appearing to Agree With Anti-Nonbinary Post - Newsweek - August 30th, 2022
- Gender Dysphoria Is Now Protected Under the Americans With Disabilities Act and It's a Pretty... - POPSUGAR - August 30th, 2022
- Boxing New Zealand supports open category in Olympic style boxing - New Zealand Herald - August 30th, 2022
- Doylestown Turns The Town Teal For Ovarian Cancer Awareness Month - Patch - August 30th, 2022
- The far right aims to eliminate trans people But the working... - Liberation - August 30th, 2022
- Hormone Replacement Therapy Will Be Available Over-The-Counter In The UK In SeptemberWe Wish The U.S. Would Follow Suit - Suggest - August 22nd, 2022
- To Your Good Health: Length of hormone treatment depends on the individual - Agri-News - August 22nd, 2022
- Menopause: Symptoms, causes, complications, diagnosis and treatment - Rising Kashmir - August 22nd, 2022
- How to Treat and Prevent Melasma with Nutrition - Intelligent Living - August 22nd, 2022
- How to eat and exercise for menopause: why you should prep now - Stylist Magazine - August 22nd, 2022
- 4 Real-Life Dating Tips for People Living with Alopecia - Everyday Health - August 22nd, 2022
- Cardiovascular health in the menopause transition: a longitudinal study of up to 3892 women with up to four repeated measures of risk factors - BMC... - August 22nd, 2022
- Hormone replacement therapy (HRT) | Health Navigator NZ - July 3rd, 2022
- Hormone-replacement therapy: current thinking - PubMed - July 3rd, 2022
- With 6.1 % CAGR, Hormone Replacement Therapy Market Size worth USD 21.49 billion by 2028 Industry Trends - Benzinga - July 3rd, 2022
- Lower Hormone Levels Linked to Risk of Sleep Apnea - Medscape - July 3rd, 2022
- Menopause and Sensitive Teeth: Symptoms, Causes, Treatments - Healthline - July 3rd, 2022
- 8 Bad Habits Leading to Breast Cancer Eat This Not That - Eat This, Not That - July 3rd, 2022
- Open, honest conversations key in reducing LGBTQ health disparities - WFYI - July 3rd, 2022
- Stopping Hormone Replacement Therapy: Cold Turkey Menopause - Breastcancer.org - July 3rd, 2022
- What the Reversal of Roe Means for the LGBTQ+ Community - Progressive.org - July 3rd, 2022
- Top 10 Hormone Replacement Therapy Industry to Look Out for in 2022 by Abbott Laboratories, Novartis, Pfizer, Inc., Mylan Laboratories - Digital... - June 22nd, 2022
- University of Medicine and Health Sciences to Host "LGBTQ+ Medicine & Theory: Providing Compassionate Care" - Yahoo Finance - June 22nd, 2022
- International Yoga Day: Womens health & yoga - Times of India - June 22nd, 2022
- Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer - Yahoo Finance - June 22nd, 2022
- 7 Strong Buy Dividend Aristocrats Are Safe-Haven Stocks to Own During a Recession - 24/7 Wall St. - June 22nd, 2022
- Hormone-Replacement Therapy Is Life-Changing: What to Consider Before Getting Started - POPSUGAR - June 13th, 2022
- High Doses of Widely-Used Cancer Drug in Hormonal Therapy Can Increase Risk of Brain Tumour in Women by Seven Times | The Weather Channel - Articles... - June 13th, 2022
- Latest study reveals that two male contraceptive pills could expand options for birth control - Interesting Engineering - June 13th, 2022
- Pride Week: Beginning Hormone Replacement Therapy : Short Wave - NPR - June 13th, 2022
- The heartbreak, hope and courage of a Maine transgender child - The Maine Monitor - June 13th, 2022
- Trans conversion therapy: What to expect when MPs debate ban - Open Democracy - June 13th, 2022
- If the menopause movement is to be truly revolutionary, it needs to include women with cancer - iNews - June 4th, 2022
- The Very Peri Summit Resource Centre: Hormone Replacement Therapy with Dr Yasmin Tan. - Mamamia - June 4th, 2022
- Finding the "Sweet Spot": Thyroid Hormone Treatment and Cardiovascular Disease - Endocrinology Network - June 4th, 2022
- Rethinking Identity and Testosterone in Imagine a Body - The New Yorker - June 4th, 2022
- Postmenopausal Years Are Creative and Satisfying for Women - Oprah Mag - June 4th, 2022